ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MNKD Stock Price » MNKD Stock News

Mannkind Share News

 Mannkind (mm) Stock Price
MNKD Stock Price
 Mannkind (mm) Stock Chart
MNKD Stock Chart
 Mannkind (mm) Stock News
MNKD Stock News
 Mannkind (mm) Company Information
MNKD Company Information
 Mannkind (mm) Stock Trades
MNKD Stock Trades

MannKind Says FDA Review Of Afrezza To Take Four More Weeks

DOW JONES NEWSWIRES MannKind Corp. (MNKD) said the U.S. Food and Drug Administration's review of its new drug application for its inhaled-insulin product for diabetics will require four additional weeks. The biopharmaceutical company, which has no products on the market currently, had been expecting FDA approval of Afrezza by Wednesday. MannKind has been hoping to succeed where larger drug makers have failed. In the mid-2000s, several companies were seeking to bring an inhaled formulation of insulin to market as an alternative to injections. The FDA initially had sought more information from MannKind in March about how the available data support the clinical utility of Afrezza in the marketplace, though the company at the time still planned a 2011 launch of the product. The FDA accepted its resubmission in July. The company also was dealt a setback in November when a former senior manager accused the drug developer of unlawful practices in its conduct of clinical trials, an accusation the company denies. Shares closed Monday at $7.97 and were inactive premarket. The stock is still down 9% this year, though it has recovered some of its losses since the FDA's action in March. -By Tess Stynes, Dow Jones Newswires; 212-416-2481;

Stock News for Mannkind (MNKD)
04/16/201503:22:53RBC Capital Trims MannKind Target Price to $10.00 (MNKD)
04/13/201506:06:41Additional Proxy Soliciting Materials (definitive) (defa14a)
04/10/201511:42:51Proxy Statement (definitive) (def 14a)
04/08/201511:59:02MannKind Corporation Shares Were Rocked in March -- Here's Why
04/05/201507:02:025 Big Losers if the Supreme Court Strikes Down Federal Obamacare...
04/03/201516:00:00Seeking Alpha's Biotech Weekly: Billion Dollar Deals, Gilead...
03/31/201519:43:15Statement of Changes in Beneficial Ownership (4)
03/26/201508:02:02Investors' Love/Hate Relationship with MannKind Corp. Stock
03/23/201509:31:24Early Adopters Embrace Afrezza, As New Inhaled Insulin Enters...
03/22/201510:12:06Did Researchers Just Unlock a Type 1 Diabetes Cure?
03/22/201509:13:08Did Researchers Just Unlock a Type 1 Diabetes Cure?
03/22/201508:01:02Confessions of a Value Investor Stuck in a High-Growth Industry
03/09/201509:07:31Mannkind: Flawed? No Competition? Overall Superior Drug?
03/06/201517:42:20After Hours Gainers / Losers
03/06/201508:37:27Statement of Changes in Beneficial Ownership (4)
03/02/201517:54:30Annual Report (10-k)
02/28/201508:32:32Analysts Weigh In On MannKind Following Q4 Results
02/25/201508:54:38Statement of Changes in Beneficial Ownership (4)
02/25/201508:53:50Statement of Changes in Beneficial Ownership (4)
02/25/201508:52:11Statement of Changes in Beneficial Ownership (4)

Mannkind and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations